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Supplementary Methods
FISH Analysis
FISH analysis was undertaken in all cases using commercially available probes (Abbott Diagnostics, Maidenhead, UK; DakoCytomation, Glostrup, Denmark) to detect deletion of 13q, 11q, 17p and trisomy 12, according to the manufacturers' instructions as previously described (1). Chromosomal analysis was performed and described according to the International System for Human Cytogenetic Nomenclature (2). ZAP70 and CD38 expression were determined as previously described (3) (4), where 10% and 30% positive cells were classed as positive or highly expressive, respectively. IGHV genes were sequenced as previously described (5) and a cut-off of ≥98% germ-line homology was taken to define the unmutated subset.
Mutational screening and sequencing
For each of the seven genes, we aimed to capture the majority of previously reported CLL specific somatic variations. Each genomic DNA sample (gDNA) was subjected to whole genome amplification (WGA) using the Illustra GenomiPhi V2 Amplification Kit® (GE Healthcare) prior to mutational screening. With the exception of the FBXW7 (direct Sanger Sequencing for all samples), all genes were screened using high-resolution melt (HRM) analysis and subsequent Sanger sequencing as previously described (6, 7) . Primer sequences are shown in Supplementary Table 7 . PCR products showing altered melt patterns were sequenced. All detected changes were sequence validated on genomic DNA (gDNA) from the archival sample. A randomly selected subset of 100 genomic DNA samples that exhibited normal HRM melt profiles on WGA material was directly sequenced for SF3B1
and XPO1. In doing so, we found no additional mutations. For NOTCH1 we screened a 399bp section of exon 34 (amino acids 2405-2525), where all of the PEST domain mutations have been found (8) (9) (10) (11) . Further analysis of the c.7544_7545delCT, referred to as 'delCT' variant was performed using PCR-based fragment analysis and KASPar genotyping and is detailed below. We screened exons 14, 15 and 16 of SF3B1 and exons 15 and 16 of XPO1 capturing the majority of previously reported disease specific variations (8, (12) (13) (14) . 
Further analysis of the NOTCH delCT variant
To further assess the sensitivity of the HRM approach for NOTCH1, we identified cases with the P2515Rfs*4 (c.7544_7545delCT, referred to as 'delCT') variant using PCR-based fragment analysis
[PCR-FA, n= 372] and allele-specific PCR [n= 213 ]as previously described for the CLL4 cohort (7). For the PCR-FA, the delCT variant was identified using PEST2 domain-specific primers (Forward:
GTGACCGCAGCCCAGTTC, reverse: AAAGGAAGCCGGGGTCTC) as previously described (15) . PCR products were sized using the LT3500 (Life Technologies) and the 271bp wild-type and 269bp mutant fragments were identified using GeneMapper (v4.1) software (Life Technologies). Allele-specific PCR for the deflect variant was performed by KBiosciences (http://www.kbiosciences.co.uk) using their fluorescence-based competitive allele-specific PCR (KASPar). 106 duplicates were included and the concordance between duplicates was >99%. Sample processing with PCR-FA and KASPar technologies were performed blindly in independent laboratories. Using these two approaches, we confirm the sensitivity of our HRM approach which showed a 100% concordance with our PCR-FA and KASPar analysis. Supplementary table 1 
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